Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM: LY3884963 in FTD-GRN
NCT04408625Phase 2Active, not recruiting
- Sponsor
- Prevail Therapeutics Inc.
- Start
- Nov 2020
- Primary completion
- Nov 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 6
01
Overview
A Phase 2 trial of LY3884963 in frontotemporal dementia (FTD), sponsored by Prevail Therapeutics Inc.. Started Nov 2020; status: active, not recruiting.
02
Drugs
LY3884963
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT04408625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408625.